688389.SHG Shenzhen Lifotronic Technology Co
- Market cap
- CNY 5.08B
- P/E
- 37.1x
- P/B
- 2.31x
- ROE
- 7.2%
- Dividend yield
- 2.38%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688389.SHG undervalued?
Graham number688389.SHG trades 95.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shenzhen Lifotronic Technology Co fundamental analysis
No fundamental analysis for Shenzhen Lifotronic Technology Co yet.
Shenzhen Lifotronic Technology Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shenzhen Lifotronic Technology Co
Shenzhen Lifotronic Technology Co., Ltd. researches, develops, manufactures, and markets medical devices for diagnostics, therapy, clinical medicine, skin, and human health related purposes in China. It offers a comprehensive range of in vitro diagnostic equipment and reagents, including electrochemiluminescence immunoassay analyzers, glycated hemoglobin analyzers, specific protein analyzers, blood analyzers, and related testing reagents, serving hospitals, health check-up c…
Full company profileShenzhen Lifotronic Technology Co financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shenzhen Lifotronic Technology Co annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 175M | 251M | 323M | 423M | 554M | 778M | 983M | 1.15B | 1.15B | 1.04B | 1.24B |
| Gross Profit | 105M | 152M | 192M | 254M | 335M | 476M | 571M | 701M | 763M | 1.04B | 777M |
| Operating Income | -10.7M | 63.2M | 89.6M | 113M | 157M | 203M | 256M | 345M | 378M | 182M | 220M |
| EBITDA | 20.6M | 70.2M | 96.6M | 122M | 168M | 221M | 283M | 377M | 421M | 218M | 150M |
| Net Income | 10.4M | 56.4M | 81.1M | 101M | 144M | 190M | 251M | 329M | 345M | 186M | 153M |
| EPS | 0.20 | 0.16 | 0.21 | 0.26 | 0.34 | 0.45 | 0.60 | 0.77 | 0.81 | 0.43 | 0.36 |
| Balance Sheet | |||||||||||
| Total Assets | 498M | 710M | 812M | 1.18B | 1.29B | 1.47B | 1.82B | 2.33B | 2.89B | 2.81B | 2.80B |
| Total Liabilities | 127M | 123M | 144M | 129M | 146M | 217M | 377M | 534M | 845M | 701M | 690M |
| Shareholders' Equity | 371M | 587M | 668M | 1.05B | 1.14B | 1.26B | 1.44B | 1.80B | 2.05B | 2.12B | 2.11B |
| Cash & Short-term Investments | 411M | 497M | 517M | 820M | 845M | 809M | 932M | 1.31B | 1.80B | 1.57B | 1.43B |
| Total Debt | - | 3.32M | - | 600K | 2.10M | 4.13M | 133M | 242M | 600M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 28.0M | 35.3M | 81.1M | 91.8M | 136M | 182M | 272M | 304M | 296M | 281M | - |
| Capital Expenditure | 32.2M | 119M | 73.4M | 67.3M | 54.1M | 122M | 184M | 48.6M | 62.0M | 83.4M | 103M |
| Free Cash Flow | -4.20M | -84.2M | 7.72M | 24.5M | 82.3M | 60.5M | 88.1M | 255M | 234M | 198M | 118M |
| Ratios | |||||||||||
| ROE | 2.8% | 9.6% | 12.1% | 9.6% | 12.6% | 15.2% | 17.5% | 18.3% | 16.8% | 8.8% | 7.2% |
| ROA | 2.1% | 7.9% | 10.0% | 8.5% | 11.2% | 12.9% | 13.8% | 14.1% | 11.9% | 6.6% | 5.4% |
| Net Profit Margin | 5.9% | 22.5% | 25.1% | 23.8% | 26.0% | 24.5% | 25.6% | 28.7% | 30.1% | 17.9% | 12.3% |
| Debt to Equity | - | 0.01x | - | 0.00x | 0.00x | 0.00x | 0.09x | 0.13x | 0.29x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shenzhen Lifotronic Technology Co dividends
- Dividend yield
- 2.38%
- Forward dividend
- 0.28 CNY
- Payout ratio
- 64.9%
- Ex-dividend date
- May 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 121M | 0.28 | 64.9% |
| 2024 | CNY 125M | 0.29 | 36.2% |
| 2023 | CNY 103M | 0.24 | 31.5% |
| 2022 | CNY 75.2M | 0.18 | 29.9% |
| 2021 | CNY 75.2M | 0.18 | 39.5% |
| 2020 | CNY 50.7M | 0.12 | 35.2% |
| 2019 | CNY 60.0M | 0.16 | 59.7% |
| 2018 | CNY 171K | 0.00 | 0.2% |
| 2017 | CNY 538K | 0.00 | 1.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shenzhen Lifotronic Technology Co
- Insiders 52.86%
- Institutions 7.46%
- Public & others 39.68%
- Shares outstanding 428M
- Free float 209M
Shenzhen Lifotronic Technology Co company profile
- Company name
- Shenzhen Lifotronic Technology Co
- Ticker
- 688389.SHG
- ISIN
- CNE100005WZ5
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,756
- Fiscal year end
- December
- Address
- Pumen Technology Headquarters Building, No. 8, Shenzhen, China, 518000
- Phone
- 86 755 2901 6066
- Website
- lifotronic.com
About Shenzhen Lifotronic Technology Co
Shenzhen Lifotronic Technology Co., Ltd. researches, develops, manufactures, and markets medical devices for diagnostics, therapy, clinical medicine, skin, and human health related purposes in China. It offers a comprehensive range of in vitro diagnostic equipment and reagents, including electrochemiluminescence immunoassay analyzers, glycated hemoglobin analyzers, specific protein analyzers, blood analyzers, and related testing reagents, serving hospitals, health check-up centers, and third-party medical testing institutions. The company also provides clinical medical solutions, such as intelligent venous thromboembolism (VTE) prevention systems, wound treatment devices, precision medicine equipment, and pain rehabilitation products for medical institutions; dermatological aesthetics, such as pulsed light therapy devices, shock wave therapy devices, laser therapy machines, and other energy-based medical aesthetic equipment; and therapeutic products comprising respiratory and ICU, and wound care; electromagnetic and pneumatic shockwave products. In addition, the company provides medical and aesthetic, and laser hair removal products, as well as offers E-training services. Further, it offers medical and beauty-related products. Additionally, the company exports its products. Shenzhen Lifotronic Technology Co., Ltd. was founded in 2008 and is headquartered in Shenzhen, China.
Shenzhen Lifotronic Technology Co management
7- Mr. Ming Long HuDirector & GM · born 1969
- Ms. Hong WangCFO & Director · born 1966
- Mr. Ying ZengDirector & Deputy GM · born 1969
- Ms. Man LuBoard Secretary · born 1990
- Mr. Liang QiuDeputy General Manager · born 1971
- Mr. Dawei LiDeputy General Manager · born 1978
- Jingyi LuoHead of the Accounting Department & Accounting Supervisor